Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy

References

• Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683–1691.
   PubMed Web of Science ®Google Scholar
• Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56(4):918–928.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–1917.
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Di Maio M, Silletta M, et al. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS One. 2015;10(7):e0133488.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.
   PubMed Web of Science ®Google Scholar
• Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.
   PubMed Web of Science ®Google Scholar
• Paul SB, Gulati MS, Sreenivas V, et al. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology. 2007;72(1):117–123.
   PubMed Web of Science ®Google Scholar
• Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001;34(4):603–635.
   PubMed Web of Science ®Google Scholar
• Lai Q, Avolio AW, Manzia TM, et al. Role of alphafetoprotein in selection of patients with hepatocellular carcinoma waiting for liver transplantation: must we reconsider it? Int J Biol Markers. 2011;26(3):153–159.
   PubMed Web of Science ®Google Scholar
• Tsai MC, Wang JH, Hung CH, et al. Favorable α-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2010;25(3):605–612.
   PubMed Web of Science ®Google Scholar
• Shao YY, Lin ZZ, Hsu C, et al. Early alpha fetoprotein response predicts treatment efficacy of anti-angiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010;116(19):4590–4596.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Sauzay C, Petit A, Bourgeois AM, et al. Alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta. 2016;463:39–44.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen Y, Ge N, et al. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization. Ann Surg Oncol. 2012;19(11):3540–3546.
   PubMed Web of Science ®Google Scholar
• Chan SL, Mo FKF, Philip J, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009;27(3):446–452.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao Y, Jia J, et al. The prognostic value of alpha-fetoprotein response for advanced-stage hepatocellular carcinoma treated with sorafenib combined with transarterial chemoembolization. Sci Rep. 2016;6(1):19851.
   PubMed Web of Science ®Google Scholar
• Oyama K, Koda M, Sugihara T, et al. Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol. 2015;3(3):655–662.
   PubMed Web of Science ®Google Scholar
• Chou WC, Lee CL, Yang TS, et al. Changes in serum alpha-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review. J Formos Med Assoc. 2018;117(2):153–163.
   PubMed Web of Science ®Google Scholar
• Memon K, Kulik L, Lewandowski RJ, et al. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012;56(5):1112–1120.
   PubMed Web of Science ®Google Scholar
• Kao WY, Chiou YY, Hung HH, et al. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. Clin Radiol. 2012;67(5):429–436.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Tai DI, Chen TJ, et al. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver. 1986;6(3):133–137.
   PubMedGoogle Scholar
• Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27(34):5734–5742.
   PubMed Web of Science ®Google Scholar
• Liu C, Xiao GO, Yan LN, et al. Value of α-fetoprotein in association with clinico-pathological features of hepatocellular carcinoma. World J Gastroenterol. 2013;19(11):1811–1819.
   PubMed Web of Science ®Google Scholar
• Peng SY, Chen WJ, Lai PL, et al. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta catenin mutations. Int J Cancer. 2004;112(1):44–50.
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhu M, Li W, et al. Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells. J Cell Mol Med. 2016;20(3):549–558.
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim HS, Park JW. Higher ratio of serum alpha-fetoprotein could predict outcomes in patients with hepatitis B Virus-associated hepatocellular carcinoma and normal alanine aminotransferase. PLoS One. 2016;11:1–12.
   Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380.
   PubMed Web of Science ®Google Scholar
• Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115(3):616–623.
   PubMed Web of Science ®Google Scholar